Study drug for cholangiocarcinoma after prior treatments
Part of Cancer clinical trials.
This Phase 2 trial tests 3D185 used alone for people with cholangiocarcinoma (bile duct cancer) that has grown despite earlier cancer treatment. It also looks at whether it’s safe and effective for tumors with certain FGF/FGFR gene changes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed cholangiocarcinoma based on lab tests of tissue or cells
- Your cancer has progressed after at least one previous type of anti-cancer medicine
- Your tumor must be tested for FGF/FGFR gene changes
- You have measurable tumors on scans (doctors can track size or spread)
- Your general condition is good enough—ECOG performance status of 0 to 2
- You are expected to live at least 12 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether treatments chosen based on the specific gene changes in your bile duct cancer can work better. It's for people with advanced cancer that hasn't responded to standard therapy.
This trial tests HMPL-453 to treat advanced intrahepatic cholangiocarcinoma (bile duct cancer) that has an FGFR2 change. It may help shrink tumors or control the disease in people whose cancer has not responded well to prior treatment.
This trial tests different treatments for advanced bile duct or gallbladder cancer based on individual tumor features. It may help people who have not had prior therapy for their cancer.
This trial tests a combination of chemotherapy drugs (gemcitabine, cisplatin, nab-paclitaxel) with an immunotherapy (rilvegostomig) before and after surgery for intrahepatic cholangiocarcinoma that can be completely removed. It aims to see if this approach improves outcomes.
This trial tests a specific chemotherapy after surgery for people with stage II or III bile duct, gallbladder, or ampullary cancer. It may help reduce the chance of cancer coming back.
This Phase 2 trial tests a combination of lenvatinib, an immunotherapy drug (tislelizumab), and chemotherapy (gemcitabine plus cisplatin) for advanced bile duct cancer that cannot be removed with surgery. It aims to see whether this treatment can shrink tumors and improve outcomes, especially for people who have not yet had immunotherapy.
Hear when a new Cholangiocarcinoma,Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.